Ad hoc announcement pursuant to Art. 53 LR Basel, June 21, 2021 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit issued a new, negative decision regarding. | June 21, 2022
Novartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New Jersey . | May 5, 2022
CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared to best available therapy1,2 Graft-versus-host disease is a. | March 25, 2022
ZURICH -Swiss voters rejected a proposal by animal rights activists to make Switzerland the first country to ban medical and scientific experiments on animals, but approved tougher restrictions on. | February 13, 2022
Novartis forecast its
sales and core operating profit would grow at a mid-single-digit
rate this year, as the Swiss pharmaceuticals group nears a
decision on whether to keep or sell its generics. | February 2, 2022